Implementing precision medicine in oncology: The IMPACT trials

The latest understanding of breakthrough cancer pain management

Editor's Choice for June 2018

Expert insight: The basic medical understanding of neutropenia and general clinical considerations

MASCC 2018: Chemotherapy-induced neutropenia and the role of G-CSFs

ASCO 2018 conference round up

Half of CLL patients who relapse on ibrutinib harbour BTK/PLCG mutations

Venetoclax in patients with previously treated WM

ICLL07 FILO study: Minimal residual disease still detectable after first line combination therapy

Even late progressors with high risk factors in PRIMA prognostic index are more likely to die

Patient relevant outcomes and advocacy

The mutational landscape of AML